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Toxoplasma gondii, an Apicomplexan parasite, causes significant morbidity andmortality,
including severe disease in immunocompromised hosts and devastating congenital
disease, with no effective treatment for the bradyzoite stage. To address this, we
used the Tropical Disease Research database, crystallography, molecular modeling,
and antisense to identify and characterize a range of potential therapeutic targets for
toxoplasmosis. Phosphoglycerate mutase II (PGMII), nucleoside diphosphate kinase
(NDK), ribulose phosphate 3-epimerase (RPE), ribose-5-phosphate isomerase (RPI),
and ornithine aminotransferase (OAT) were structurally characterized. Crystallography
revealed insights into the overall structure, protein oligomeric states and molecular
details of active sites important for ligand recognition. Literature and molecular modeling
suggested potential inhibitors and druggability. The targets were further studied with
vivoPMO to interrupt enzyme synthesis, identifying the targets as potentially important to
parasitic replication and, therefore, of therapeutic interest. Targeted vivoPMO resulted in
statistically significant perturbation of parasite replication without concomitant host cell
toxicity, consistent with a previous CRISPR/Cas9 screen showing PGM, RPE, and RPI
contribute to parasite fitness. PGM, RPE, and RPI have the greatest promise for affecting
replication in tachyzoites. These targets are shared between other medically important
parasites and may have wider therapeutic potential.
Keywords: Toxoplasma gondii, PPMO, phosphoglycerate mutase, nucleoside diphoshate kinase, ribulose-3-
phosphate epimerase, ribose-5-phosphate isomerase, ornithine aminotransferase, crystallography
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INTRODUCTION
Toxoplasma gondii is one of the most significant parasites
that impacts human health, with estimates that as many as
one third to one half of the human population are infected
(Montoya and Liesenfeld, 2004; Furtado et al., 2011; Torgerson
and Mastroiacovo, 2013; Flegr et al., 2014; McLeod et al., 2014;
Lykins et al., 2016). A relative of the parasite that causes malaria,
T. gondii is an intracellular parasite that has two major life stages
in humans, tachyzoites and bradyzoites. Tachyzoites cause acute
infection, while bradyzoites are the encysted, dormant life stage
responsible for reactivation disease. While treatment is available
for the acute infection, there is currently no effective medication
for the bradyzoite stage (McLeod et al., 2014). Additionally,
parasites can be passed to a fetus in uterowhen a pregnant woman
is acutely infected during gestation. This can cause chorioretinitis
and neurological complications in the fetus (McLeod et al., 2012).
Moreover, there is increasing understanding of the potential
long-term sequelae of chronic infection with T. gondii on risk
of neurodegenerative disease and malignancy (Ngô et al., 2017).
Treatment for active infection exists but is limited by toxicity and
hypersensitivity. Thus, new therapeutic targets andmedicines are
needed, with several potential solutions in development (Zhou
et al., 2014; McPhillie et al., 2016; Sidik et al., 2016).
At the Center for Structural Genomics of Infectious Diseases
(CSGID), the first Toxoplasma Structural Genomics Pipeline
was established. Subsequently, CSGID began selecting parasite
proteins for structural characterization using established
approaches capable of successful identification of potential
drug targets, coupled with the Tropical Diseases Research
(TDR) Database (Anderson, 2009; Crowther et al., 2010;
Magariños et al., 2012). Herein, 5 soluble enzymes were selected
for further study. This process was made possible due to
the integration of large amounts of genomic, biochemical,
and pharmacological data by the TDR Database, which
provides evidence collectively generated by the scientific
community concerning potential molecular targets and
inhibitory compounds that have properties consistent with
Lipinski’s rules for orally available drugs (Lipinski, 2004). The
targets studied herein were crystallized and their structures
characterized, as structural studies have potential to inform
molecular targeting and medicinal chemistry can facilitate
development of novel anti-parasitic compounds.
We further hypothesized that using phosphorodiamidate
morpholino oligomers linked to a cellular delivery moiety, such
as either an octaguanidinium dendrimer [Vivo-Morpholinos
(vivoPMOs)], or arginine-rich peptide, we would decrease
expression of these enzymes, identified as potential drug targets
by the Toxoplasma Structural Genomic Pipeline, in YFP-
expressing T. gondii tachyzoites, and that down-regulation of
these enzymes would result in decreased replication as quantified
by fluorescent intensity. The approach of using morpholinos to
target specific parasitic enzymes has been successful in previous
studies (Lai et al., 2012; McPhillie et al., 2016). VivoPMOs are
typically used to decrease gene expression by one of two different
mechanisms, namely mechanical disruption of interactions
between RNA and snRNP, thereby preventing splicing of introns,
resulting in nonsense-mediated decay of the transcript and/or
defective protein upon translation, and through direct prevention
of translation by blocking interactions between mature mRNA
and the ribosome. In preventing effective protein expression,
we could determine whether a particular enzyme contributed
to parasite replication, suggesting its potential as a therapeutic
target.
Molecular transporters can deliver PMOs and small inhibitory
molecules of therapeutic value. Transductive peptides or
octaguanidinium dendrimer of a Vivo-Morpholino (Gene Tools,
Philomath, Oregon) deliver PMOs or other molecules across
cell membranes. Octaarginine can carry small molecules into
the retina (McLeod et al., 2013). Similar arginine-rich cell-
penetrating peptides can access other places where medication
transport is problematic; for example, rabies virus glycoprotein-
tagged small molecules are capable of passing through the blood-
brain barrier and octaarginine-conjugated small molecules, for
example, cross into encysted bradyzoites (Samuel et al., 2003; Liu
et al., 2009).
The enzymes selected from the TDR database as small
and tractable for expression and crystallization included:
phosphoglycerate mutase II (hereafter referred to as PGM),
nucleotide diphosphate kinase (NDK), ribulose phosphate 3-
epimerase (RPE), ribose-5-phosphate isomerase (RPI), and
ornithine aminotransferase (OAT). Information about candidate
inhibitors of these apicomplexan enzymes is summarized in
Table 1.
METHODS
Cloning, Expression, and Purification
Five genes from T. gondii ME49 (GI: 237843677, 237844373,
237835673, 237834547, and 237832613) corresponding to a
putative phosphoglycerate mutase II (TgPGM; residues 1–265
of the original CSGID entry; this entry was modified in 2012;
see original NCBI Reference Sequence: XP_002371136.1), a
putative nucleoside diphosphate kinase (TgNDK) (residues 1–
155), ribulose phosphate 3-epimerase (TgRPE) (residues 1–
230), a putative ribose 5-phosphate isomerase (TgRPI) (residues
1–259), and a putative ornithine aminotransferase (TgOAT)
(residues 17–441), respectively, were cloned into the ligation-
independent-cloning (Aslanidis and de Jong, 1990) isopropyl β-
D-1-thiogalactopyranoside (IPTG)-inducible pMCSG28 vector
for recombinant bacterial expression in BL21(DE3)/pMagic
Escherichia coli (E. coli). All clones were obtained from J. Craig
Venter Institute, a CSGID partner, and submitted into the CSGID
protein production pipeline (Figure 1) as IDP92076 (TgPGM),
IDP92074 (TgNDK), IDP92047 (TgRPE), IDP92040 (TgRPI),
and IDP92102 (TgOAT). The pMCSG28 vector possesses a
purification tag including 6×His affinity sequence and a Tobacco
Etch Virus (TEV) protease cleavage site. The E. coli cells were
induced with 1mM IPTG at 25◦C after the optical density of cells
in culture flasks reached 0.6 at 600 nm under 37◦C and constant
aeration at 200 rpm. Terrific Broth (TB) (PGM, NDK, and RPE)
and the Se-Met MCSG-M9 (Medicilon Inc.) (RPI) medium was
used. Overnight induction was completed by collecting cells at
6,000 rpm, 4◦C for 10min. Cells’ paste was resuspended in chilled
Lysis Buffer [43mM Na2HPO4, 3.25mM citric acid, 250mM
NaCl, 100mM ammonium sulfate, 5% glycerol, 5mM imidazole,
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FIGURE 1 | The Toxoplasma Structural Genomics Pipeline identified promising targets with good predicted druggability (Phase III) and outstanding interest to the
Toxoplasma research community (Phase I, II). Toxoplasma proteins were selected for Phase I from published work up to 2009 and communicated with the research
laboratories. Phase II included proteins from published and unpublished studies suggested by international researchers at the end of 2011. Phase III candidates were
selected from the Tropical Diseases Research Database (TDRT). Proteins judged very unlikely to crystallize based on analysis by XtalPred were eliminated (Slabinski
et al., 2007). Several structures solved have already been described (Ruan et al., 2015; Tonkin et al., 2015; Dubey et al., 2017). This crystallography pipeline remains
available for production and solution of structures of proteins for scientists in the Toxoplasma research community.
1.5mM magnesium acetate, 1mM CaCl2, 0.08% n-Dodecyl β-
D-maltoside (DDM), 5mM β-mercaptoethanol (BME)] pH 7.8
followed by sonication on ice. Crude sonication mixture was
centrifuged at 19,000 rpm, 4◦C for 40min to obtain soluble
fraction containing target protein, which was applied onto a
5-ml Ni-NTA column (GE Healthcare, Piscataway, NJ) for
purification. The column was washed with buffer containing
10mM Tris-HCl pH 8.3, 500mM NaCl, 25mM imidazole and
5mM BME to remove non-specifically bound E. coli proteins,
followed by elution of target protein with 500mM imidazole
in the 10mM Tris-HCl buffer pH 8.3 containing 500mM NaCl
and 5mM BME (buffer A). A HiLoadTM 26/60 SuperdexTM 200
column (GE Healthcare, Piscataway, NJ) was used to further
purify target protein in the buffer A. Purity of all proteins
was analyzed by SDS-PAGE. Pooled fractions were concentrated
and stored at −80◦C for further use or used in screening
crystallization conditions.
Crystallization, X-Ray Data Collection, and
Structure Determination
Each target protein was crystallized by the vapor-diffusion
sitting-drop method mixing 1 µL of the protein in buffer A and
1 µL of a crystallization screen solution at 22◦C. Single crystals
were soaked in a crystallization condition for cryoprotection and
flash frozen in liquid nitrogen for monochromatic X-ray data
collection. Data were collected at 100K from a single frozen
crystal at the LS-CAT beamline 21-ID-F (λ = 0.97872 Å) at the
Argonne National Laboratory (ANL), Advanced Photon Source
(APS). Diffraction images were collected in oscillation mode and
processed with HKL-3000 (Minor et al., 2006). Crystal structures
of TgPGM, TgNDK, TgRPE, and TgOAT were determined by
molecular replacement using Phaser (McCoy et al., 2007) from
CCP4 suite (Winn et al., 2011). Initial molecular replacement
solutions were rebuilt with ARP/wARP (Morris et al., 2003).
Crystal structure of TgRPI was determined by single-wavelength
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anomalous dispersion (SAD) method in HKL-3000 (Minor
et al., 2006). Non-Crystallographic Symmetry (NCS) restrains
and Translation-Libration-Screw (TLS) groups refinement in
REFMAC v.5.7 (Murshudov et al., 2011) were used to improve the
quality of the structures. Coot (Emsley and Cowtan, 2004; Emsley
et al., 2010) was used tomanually check structures after each cycle
of refinement in REFMAC and correct for side chain rotamers
and fitting. The final models were validated with the Protein Data
Bank (PDB) validation server (ADIT validation server; https://
validate-rcsb-2.wwpdb.org/) and MolProbity (http://molprobity.
biochem.duke.edu/) (Davis et al., 2007; Chen et al., 2010). Figures
presenting crystal structures were prepared in the graphical
program PyMol (The PyMOL Molecular Graphics System,
Version 2.0 Schrödinger, LLC). Crystallization conditions, data-
collection, structure determination and refinement statistics are
summarized in Table 2. Crystal structures are described in
Figures 2–6.
Data Accessibility
Coordinates and structure factors of the determined crystal
structures were deposited to Protein Data Bank (www.rcsb.org)
(Berman et al., 2000). Diffraction images for the deposited crystal
structures can be found at the CSGID website (http://www.csgid.
org/csgid/pages/home).
Crystal Structure Data Analysis
We used CATH/Gene3D v4.1 (http://www.cathdb.info/) (Sillitoe
et al., 2015; Lam et al., 2016) to assess domain composition of
studied proteins. Oligomeric state of the proteins and buried
surface area (BSA) of multimers were estimated from crystal
structure coordinates using PISA (http://www.ebi.ac.uk/pdbe/
pisa/pistart.html) (Krissinel and Henrick, 2005, 2007; Krissinel,
2009). The number of intermolecular bonds that may contribute
to protein quaternary structure was estimated from the structure
coordinates using PDBsum (http://www.ebi.ac.uk/thornton-srv/
databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=index.html) (de
Beer et al., 2014). Assessment of metal binding sites was done
with help of the CheckMyMetal server (http://csgid.org/csgid/
metal_sites) (Zheng et al., 2017). Protein structure comparison
service PDBeFold at European Bioinformatics Institute (http://
www.ebi.ac.uk/msd-srv/ssm) was used to identify structural
homologs (Krissinel and Henrick, 2004). Pair-wise structural
alignments were performed with DaliLite v.3 (https://www.ebi.
ac.uk/Tools/structure/dalilite/) (Hasegawa and Holm, 2009).
Molecular Modeling
Schrödinger 2015-3, maestro v10.3 was used for binding site
identification (SiteMap) on the five enzymes, and therefore,
predict “druggability” by small molecules (Schrödinger Release
2015-3, 2018). A SiteScore threshold of 0.80 (with > 0.80
suggesting druggability) is used in this regard (Halgren, 2007).
Cell Culture
Human foreskin fibroblasts (HFF) were maintained in Iscove’s
Modified Dulbecco’s Medium (IMDM) supplemented with
10% fetal bovine serum (FBS) and PENSTRA (penicillin and
streptomycin). Cells were maintained at 37◦C and 5% CO2.
VivoPMO Design
The vivoPMOs were designed using genomic DNA sequences
obtained from ToxoDB (accession numbers for genomic DNA
sequences: PGM-TGME49_297060, NDK-TGME49_295350,
RPE-TGME49_047670, RPI- TGME49_039310, OAT-
TGME49_069110) with exon/intron junctions identified.
One of these junctions was identified in each target gene and
a vivoPMO was designed to be complementary to nucleotides
on both sides of said junction. A diagrammatic representation
of vivoPMO structure and RNA binding is in Figure 7A. The
sequences of these morpholinos can be found in Figure 7B.
VivoPMO Efficacy Assay
HFFs were grown in black, flat-bottomed 96-well microplates.
HFFs were infected with 3,200 Type I RH parasites expressing
yellow fluorescent protein (YFP). This allowed quantification of
parasites in vitro post-treatment with vivoPMO. The parasites
were incubated with the cells for 1 h, to allow sufficient time
for invasion of HFFs, and were then treated with vivoPMO.
Control triplicates with only fibroblasts and with pyrimethamine
and sulfadiazine (the current standard of treatment for T. gondii
infection) were also conducted. A concentration gradient of
YFP parasites was also established, allowing quantification
of knockdown. Several replicates of this efficacy assay were
completed applying different concentrations of vivoPMO (2.5,
5, 10, and 20µM). The cells and parasites were then incubated
at 37◦C for 72 h. This timing was previously established in other
work. Fluorescence wasmeasured using a Bio-Tek SynergyTM H4
Hybrid Multi-Mode Microplate Reader. This methodology was
consistent with previous work using morpholinos in T. gondii
(Lai et al., 2012).
VivoPMO Toxicity Assay
HFFs were grown in 96-well microplates, as in the efficacy
assay. A gradient of dimethyl sulfoxide (DMSO) was used to
quantify the amount of cell death caused by the vivoPMO
in vitro. Different concentrations of vivoPMO (3.5, 5, 10, and
20µM) were used to identify the level at which toxicity occurred.
Following 72 h of incubation at 37◦C, each well was treated with
10 µL WST-1, which reacts in metabolically active, viable cells
through a complex set of chemical reactions dependent upon
glycolytic NADPH production to form formazan dyes, which can
be detected via a colorimeter. This method is also consistent with
previous work (Lai et al., 2012).
Data Analysis of Knockdown With
VivoPMO
Knockdown was analyzed statistically using student T-test
comparing parasite fluorescence between enzyme-specific
vivoPMO and off-target vivoPMO. Additionally, the enzyme-
specific vivoPMOs were compared to the levels of fluorescence
at the standardized parasite load (2000 YFP-expressing parasites
per well). Student T-test was also used to analyze toxicity data,
comparing levels of optical density at 420 nm for untreated
fibroblasts to treated cells. Statistical analysis was performed
using STATA. Results were considered significant with p< 0.05.
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TABLE 2 | Crystallization conditions, data-collection, structure determination and refinement statistics of T. gondii proteins.
Protein name PGM NDK data set I NDK data set II RPE RPI OAT
CRYSTALLIZATION CONDITIONS
Screen conditions 0.2M MgCl2,
0.1M HEPES pH
7.5, 25%
PEG3350
0.2M ammonium
sulfate, 0.1M
Bis-Tris pH 5.5,
25% PEG3350
0.2M MgCl2,
0.1M MES, 20%
PEG6000
2M ammonium
sulfate, 0.1M citric
acid pH 3.5
2.1M DL-Malic
acid pH 7.0
0.2M ammonium acetate,
0.1M Bis-Tris pH 6.5, 25%
PEG3350
Protein concentration
(mg/ml)
7.5 7.5 6 7.4 7.1 22.8
DATA COLLECTION
Space group P21212 P212121 C2 H32 P4122 P1
Unit cell parameters (Å; ◦) a = 97.2,
b = 149.5,
c = 72.1;
α = β = γ = 90.0
a = 73.4,
b = 121.6,
c = 212.3;
α = β = γ = 90.0
a=236.8, b=73.4,
c=122.7; α =γ
=90.0, β = 116.8
a = b = 138.5,
c = 349.3;
α = β = 90.0,
γ = 120.0
a = b = 95.6,
c = 112.7;
α = β = γ = 90.0
a = 56.2, b = 61.3,
c = 63.7; α = 100.6,
β = 93.2, γ = 107.7
Resolution range (Å) 30.00–2.60
(2.64–2.60)
30.00–2.40
(2.44–2.40)
30.00-1.70
(1.73-1.70)
30.00–2.05
(2.09–2.05)
30.00–2.60
(2.64–2.60)
62.10–1.20 (1.22–1.20)
No. of reflections 33,033 (1,604) 75,092 (3,725) 202,729 (10,203) 81,012 (3,999) 16,774 (818) 224,574 (11,241)
Rmerge (%) 10.6 (64.5) 8.4 (52.3) 5.9 (48.2) 7.2 (61.5) 9.4 (61.6) 4.3 (37.0)
Completeness (%) 100.0 (100.0) 99.6 (99.8) 98.5 (99.9) 100.0 (100.0) 100.0 (100.0) 91.0 (91.0)
〈I/σ (I)〉 18.3 (3.3) 18.2 (3.2) 22 (3.2) 20.1 (2.4) 44.9 (5.4) 11.2 (2.0)
Multiplicity 7.3 (7.4) 5.7 (5.8) 4.9 (4.9) 4.5 (4.5) 14.2 (14.7) 2.0 (2.0)
Wilson B factor 52.0 51.0 28.0 32.6 61.4 14.4
STRUCTURE DETERMINATION
MR initial model (PDB ID) 1xq9 1ndl 3qc3 - 3lg0
REFINEMENT
Resolution range (Å) 29.72–2.60
(2.67–2.60)
29.49–2.40
(2.46–2.40)
29.98-1.7
(1.74-1.7)
29.88–2.05
(2.10–2.05)
29.53–2.60
(2.67–2.60)
62.1–1.2 (1.23–1.20)
Completeness (%) 99. 8 (98.2) 99. 5 (99.7) 98.2 (97.04) 99. 9 (99.9) 99. 8 (99.8) 90. 8 (90.0)
No. of reflections 31,317 (2,253) 71,019 (5,181) 192,440 (13,960) 76,865 (5,594) 15,802 (1,134) 213,305 (15,538)
Rwork/Rfree (%) 19.7/23.9
(25.9/27.7)
19.2/23.8
(26.1/34.3)
15.4/19.2
(20.8/24.6)
14.9/18.7
(21.9/26.8)
16.4/20.5
(25.8/34.4)
13.3/16.5 (20.9/23.8)
Protein molecules/atoms 2/6,560 12/14,699 12/14,647 4/6,761 1/1,866 2/6,560
Solvent atoms 1,041 548 1854 513 71 1,041
Mean temperature factor
(Å2)
56.3 48.7 33.4 39.9 56.8 18.4
COORDINATE DEVIATIONS
R.m.s.d. bonds (Å) 0.011 0.007 0.010 0.010 0.012 0.021
R.m.s.d. angles (◦) 1.626 1.219 1.398 1.434 1.711 1.927
RAMACHANDRAN PLOT†
Most favored (%) 90.2 92.8 95.0 91.8 95.4 90.2
Allowed (%) 9.0 6.4 5.0 8.2 4.1 9.0
Generously allowed (%) 0.3 0.8 0.0 0.0 0.5 0.3
Outside allowed (%) 0.5 0.0 0.0 0.0 0.0 0.5
PDB Accession Code 4odi 4o0n 5bxi 4nu7 4nml 4nog
Values in parentheses are for the highest resolution shell.
†
Statistics are based on PROCHECK (Laskowski et al., 1993).
Antibody Production
Antibodies were raised in mice at the University of Strathclyde
(CR, SW). Briefly, mice were given two injections of formulated
protein with NISV (non-ionic surfactant vesicle). The vesicles
were made by melting mono-palmitoyl glycerol, cholesterol and
dicetyl-phosphate (All from Sigma, UK) in a molar ratio of 5:4:1.
10 days after the final injection, serumwas collected and tested by
Western Blot using recombinant protein and Toxoplasma lysate.
Immunofluorescence Assay (IFA)
HFF cells were grown to confluence on sterilized coverslips
in 24-well plates. Cells were fixed in 3% paraformaldehyde
∼20–24 h after infection with Type I RH-strain tachyzoites
and permeabilized in 0.25% Triton X-100. Serum from
immunized mice, coupled with another primary antibody,
RPS13, was applied at 1:500 dilution in PBS 1x/3% BSA/Triton-
X-100 and detected using either Texas Red-conjugated goat
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FIGURE 2 | Crystal structure of TgPGM (A). Ribbon representation of TgPGM monomer (left side) colored blue (N-terminus) to red (C-terminus) and tetramer of
TgPGM (right side) (B). Domain structure of TgPGM [red—an α/β/α-sandwich domain (residues 12–107 and 169–257) and blue—a domain without any defined
folding motif (residues 108–168)] (C). Pairwise structural alignment of TgPGM (gray) and BpPGM (cyan) showing active site with residues of TgPGM shown in sticks
and labeled in one-letter code. Equivalent residues of BpPGM are displayed. BpPGM binds (2R)-2,3-diphosphoglyceric acid, DG2, in the active site.
anti-mouse antibody, or Alexa-488–conjugated goat anti-rabbit
antibody. DAPI was used to stain for DNA. Coverslips were
mounted with Antifade (Molecular Probes, Eugene, OR), and
images were analyzed by high-resolution fluorescence using
deconvolution protocols. Microscopy was performed with an
inverted microscope (IX81; Olympus).
Comparison to Predicted Essentiality via
Literature CRISPR/Cas9 Screen
As an approach to identify whether target enzymes might be
essential to parasite viability and fitness, a survey was done
of phenotypic scores previously published in a genome-wide
CRISPR/Cas9 screen (Sidik et al., 2016). Gene IDs were used
and the average of the three available scores was taken. Negative
scores were considered likely to be significant contributors
to parasite fitness. Data of the genome-wide CRISPR/Cas9
screen are subsequently annotated in ToxoDB (http://toxodb.
org/toxo/), including these gene IDs: TgPGM: TGME49_297060,
TgNDK: TGME49_295350, TgRPE: TGME49_247670, TgRPI:
TGME49_239310, TgOAT: TGME49_269110.
RESULTS
Structural Genomic Pipeline for
Toxoplasma
The NIAID Structural Genomics Centers selected 265 proteins
for the Toxoplasma Structural Genomic Pipeline in three phases
(Figure 1). Phase I and II were a collaborative effort between
CSGID and the Toxoplasma research community. Proteins were
selected from published and unpublished work up to 2011.
Selection was based on the mechanisms and pathways that are
important for parasite infection and survival in human and
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FIGURE 3 | Crystal structure of TgNDK (A). Ribbon representation of TgNDK monomer (left side) colored blue (N-terminus) to red (C-terminus) and trimeric and
hexameric assemblies of TgNDK (middle and right side) (B). Pairwise structural alignment of TgPGM (gray; SO4 is shown in sticks) and human NM23-H2 transcription
factor [cyan (chain E with bound 2′-deoxyguanosine-5′-monophosphate (DG) and 2′-deoxyadenosine-5′-monophosphate (DA)] and magenta [chain B with bound
2′-deoxyguanosine-5′-monophosphate (DG)] showing active site with residues of TgNDK shown in sticks and labeled in one-letter code. Equivalent residues of
human NM23-H2 transcription factor are displayed.
animal hosts. Protein sequences were analyzed by XtalPred and
final selection was also based on their crystallization feasibility
(Slabinski et al., 2007).
Phase III utilized the TDR Database (Anderson, 2009;
Crowther et al., 2010; Magariños et al., 2012). TDR integrated
and weighed candidate drug targets based on extensive
genetic, biochemical, pharmacologic, compound desirability
and computationally-predicted druggability characteristics.
Herein, 5 soluble enzymes were selected for further study.
The genes encoding these enzymes were cloned, proteins
expressed and purified, crystallized, and crystal structures were
determined (Figures 2–6). The crystal structures have been
deposited in the PDB database in accordance with CSGID
and NIH policies. PDB codes can be found in Figure 1 and
Table 2.
Phosphoglycerate Mutase II (PGM)
The crystal structure of a putative TgPGM1 was determined and
refined to 2.6 Å resolution (PDB 4odi) (Table 2 and Figure 2A).
The P21212 asymmetric unit comprises four PGM chains [∼0.4
Å root-mean-square-deviation (r.m.s.d.) over 240 Cα atoms]
assembled in two dimers with BSA of ∼1,900 Å2, while four
chains bury a surface area of∼ 6,800 Å2 (Figure 2A). Eleven salt
bridges, 15 hydrogen-bonded and 236 van derWaals interactions
hold the tetramer in place. A sodium ion-binding site (e.g.,
NA 301/A) was identified during structure refinement. Tyr155,
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FIGURE 4 | Crystal structure of TgRPE (A). Ribbon representation of TgRPE monomer (left side) colored blue (N-terminus) to red (C-terminus) and TgRPE dimer (right
side) (B). Pairwise structural alignment of TgRPE (gray; SO4 is shown in sticks and Zn2+ as green sphere) and human RPE with bound Fe2+ (yellow ribbon),
5-O-phosphono-D-xylulose (5SR; magenta ribbon), and ribulose-5-phosphate (5RP; cyan ribbon) showing active site with residues of TgRPE are shown in sticks and
labeled in one-letter code. Equivalent residues of human RPE are displayed.
Val158, and Asn160 coordinate NA 301/A. Residues 12–257
(chain A), 15–259 (chain B), 15–257 (chain C), and 17–248 (chain
D) are present in the deposited structure.
TgPGM has an α/β/α-sandwich domain that comprises
residues 12–107 and 169–257 (Figure 2A). The domain has a
six-stranded central β-sheet flanked by helices α1, α2, α3, α6,
α7, α8, and α9, and 310-helices η1 and η6. Residues 108–168
(helices α4 and α5, and four 310 helices; η2–η5) flank the α/β/α
domain without any defined folding motif (Figure 2B). Lys115
and Arg132 of this motif comprise a portion of the active site
and together with Arg25, His26, Asn32, Thr38, Glu104, Tyr107,
His199, and Asn201of the α/β/α domain shape the entrance to
the active site (Figure 2C). An interesting feature of the structure
is a “scorpion tail” segment (residues 136–168 belonging to 310-
helices η3, η4, and η5) that lies on top of the α/β/α domain
(Figure 2B). Position of this segment within the crystal lattice
suggests that it affects oligomerization and crystal packing. The
tip of the tail possesses the sodium ion-binding site.
The structure of the Plasmodium falciparum PGM (PfPGM;
PDB 3kkk; DOI: 10.2210/pdb3KKK/pdb) is the closest homolog
of TgPGM with estimated 75% sequence identity and ∼0.6 Å
r.m.s.d. over 229 Cα atoms. The structure of the homologous
bacterial enzyme from Burkholderia pseudomallei (PDB 3fdz;
67% sequence identity; r.m.s.d. ∼1.0 Å over 230 Cα atoms)
determined in the complex with (2R)-2,3-diphosphoglyceric
reveals that TgPGM possesses identical active site residues
with an essential phospho-acceptor residue His26 (Davies
et al., 2011). Preliminary validation of this active site in
Schrödinger SiteMap gave a favorable score of 0.98. Structural
alignment of BpPGM and TgPGM demonstrates significant
main- and side-chain conformational changes at the protein
active site that would most likely take place in TgPGM during
the interconversion of its substrate 3-phosphoglycerate to 2-
phosphoglycerate (Figure 2C). Conformational differences were
also observed for residues located on the tip of the scorpion-like
tail.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9 October 2018 | Volume 8 | Article 352
Lykins et al. Therapeutic Target Characterization for Toxoplasmosis
FIGURE 5 | Crystal structure of TgRPI (A). Ribbon representation of TgRPI monomer (left side) colored blue (N-terminus) to red (C-terminus). Catalytic domain and
oligomerization domain of TgRPI with bound D-malate (MLT; sticks) and chloride ion (Cl−; green sphere) are shown on the right. (B). Unstable and stable TgRPI
dimers according to PISA prediction (C). Pairwise structural alignment of TgRPI (gray; MLT is shown in sticks and Cl− as green sphere) and TtRPI (cyan ribbon) with
bound arabinose 5-phosphate (A5P; sticks) showing active site with residues of TgRPI are shown in sticks and labeled in one-letter code. Equivalent residues of TtRPI
are displayed. Water molecules are shown as small red spheres.
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FIGURE 6 | Crystal structure of TgOAT (A). Ribbon representation of TgOAT monomer (left side) colored blue (N-terminus) to red (C-terminus). Catalytic and
N/C-termini domains with bound PLP are shown on the right (B). Dimer of TgOAT (C). Pairwise structural alignment of TgOAT (gray; PLP is shown in sticks) and hOAT
with bound PLP (cyan ribbon; PDB 1oat). Residues of TgOAT are shown in sticks and labeled in one-letter code. Equivalent lysine residues of hOAT are displayed.
Chain identifier in parentheses.
Nucleoside Diphosphate Kinase (NDK)
Crystal structures of a putative TgNDK were determined and
refined to 2.4 Å (PDB 4o0n) and 1.7 Å (PDB 5bxi) resolution
(Figure 3A and Table 2). Monomers in both TgNDK structures
are superimposed with ∼0.2–0.7 Å r.m.s.d. over 153 Cα atoms,
while monomers in 4o0n align with ∼0.2–0.7 Å r.m.s.d (153 Cα
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FIGURE 7 | (A) Schematic of Interaction Between vivoPMO and RNA. (B) Sequences for PMO. Sequences for all enzymes were designed to be complementary to
regions overlapping splice sites so as to prevent appropriate interaction between mRNA and the spliceosome predicted to lead to the production of a non-functional
protein product.
atoms) and monomers in 5bxi align with∼0.2–0.6 Å r.m.s.d (153
Cα atoms). In both structures, TgNDK forms a hexamer with an
average BSA of∼18,900 Å2 (Figure 3A). Comparison of TgNDK
with known crystal structures of homologs proteins suggests that
the TgNDK hexamer is likely a biologically functional assembly
(Min et al., 2002; Vieira et al., 2015).
Residues 156–160 (GENLY) of the C-terminal tag in chains
D and G only of the 5bxi structure were modeled, while they
are absent in all chains of the 4o0n structure. These residues
protrude to the solvent and make contacts with symmetry-
related hexamer. The side chain of Tyr160 is spatially positioned
in a nucleotide base-binding pocket of the active site of a
symmetry-related molecule (not shown). In addition, residues
56–64 (DLKGKPFFP; chain C of 5bxi) that belong to the C-
terminus of helix α3, 310 helix η1, η1–α4 loop, and the N-
terminus of helix α4 are disordered. This peptide stretch may
constitute a portion of a nucleotide base-binding pocket of
the active site. Superposition of all twelve chains in 5bxi and
4o0n structures revealed that this segment has similar secondary
structure conformations. Presumably, lack of favorable crystal
contacts resulted in its disorder in chain C of the 5bxi structure.
TgNDK adopts an α/β/α sandwich fold with four β strands
and eight surrounding α helices (Figure 3A). The putative active
site of TgNDK was identified based on a pairwise structural
alignment with the crystal structure of human NM23-H2
transcription factor in complex with the dinucleotide d(AG)
(PDB 3bbb; Dexheimer et al., 2009). The active site comprises
residues Lys14, Tyr54, Leu57, Lys60, Phe62, Leu66, Thr96,
Val114, and Gly115 (Figure 3B), where analysis by Schrödinger
SiteMap revealed a score of 0.99 (using PDB 4o0n), indicating
a “druggable” pocket. Crystals of TgNDK (PDB 4o0n) grew in
the presence of ammonium sulfate and, thus, several sulfate ions
were identified and modeled during refinement. Superposition
of TgNDK with the structure of human NM23-H2 transcription
factor (∼67% homology; ∼0.6 Å r.m.s.d. over 148 Cα atoms)
revealed that a sulfate ion (e.g., SO4 201/A) binds close to
a phosphate-binding pocket of the active site (Figure 3B). A
bicarbonate ion (e.g., BCT 201/A) was modeled at a similar
location in the 5bxi structure. Similar main- and side-chain
rearrangements of residues of the active site as seen in NM23-H2
are expected in TgNDK upon binding its substrate.
Ribulose Phosphate 3-Epimerase (RPE)
Crystal structure of TgRPE was determined and refined to 2.05
Å resolution (PDB 4nu7; Table 2 and Figure 4A). TgRPE adopts
an aldolase-type TIM-barrel α/β fold resembling homologous
RPEs. Four chains of TgRPE (∼0.3–0.5 Å r.m.s.d. over 225 Cα
atoms) in the H32 asymmetric unit form two dimers (A–C and
B–D; Figure 4A) each burying a surface area of ∼3,500 Å2. The
dimer is similar to one observed for known RPEs (Williamson
and Wood, 1966; Jelakovic et al., 2003; Caruthers et al., 2005;
Liang et al., 2011). Helices α1 and α2, and the β2–α2 and η1– α1
loops ofTgRPE comprise the dimer interface with 4 salt bridges, 8
hydrogen-bonded and 130 van der Waals contacts (e.g., between
chains A and C). PISA prediction and crystal packing analysis
revealed a hexameric assembly of TgRPE (BSA is∼13,300 Å2; not
shown) that has been reported previously for homologous RPEs
(Kopp et al., 1999; Wise et al., 2004; Akana et al., 2006).
A Zn2+ (e.g., ZN 303/A) ion was modeled per each chain of
TgRPE, with His37, Asp39, His71, Asp182 and a water molecule
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coordinating the metal (Figure 4B). Similar coordination has
been reported for D-xylulose 5-phosphate co-crystallized with
human RPE enzyme (PDB: 3ovr) (Liang et al., 2011) (Figure 4B).
PDBeFold identified human RPE as the closest homolog of
TgRPE (∼0.9 Å r.m.s.d. over 215 Cα atoms; 52% sequence
identity). The CheckMyMetal analysis identified that Co2+ and
Cu2+ may also bind in a similar position as zinc in TgRPE. It is
known that the RPE enzymes can utilize Fe2+, Co2+, and Mn2+
for catalysis (Jelakovic et al., 2003; Wise et al., 2004; Caruthers
et al., 2005; Akana et al., 2006; Liang et al., 2011). Residues of
the metal binding site are strictly conserved in the RPE enzymes.
Structural superposition revealed that Fe2+ in ferrous-, substrate-
and product-bound human RPE structures is ∼1.0 Å away from
the position of Zn2+ in TgRPE. We also compared TgRPE
structure with two other RPEs structures (PDBs 1tqx and 1h1z)
(Jelakovic et al., 2003; Caruthers et al., 2005) that have zinc and
SO2−4 bound in similar locations as TgRPE. Positions of zinc and
side chains of the Zn2+-coordinating residues are similar in the
three compared structures (not shown). Other RPE structures
with bound Zn2+ and other than SO2−4 ligands (e.g., PDBs 2fli,
3qc3, and 5umf) have similar positions of Zn2+ and side chains
of the metal-binding residues (Akana et al., 2006; Joint Center
for Structural Genomics, 2011; Dranow et al., 2017). Additional
experiments are needed to confirm the biological importance of
zinc in the TgRPE-based catalysis. This metal-binding region
was analyzed for “druggability” and scored 1.04 (Schrödinger
SiteMap).
Crystals of TgRPE grew in the presence of 500mM NaCl and
2M ammonium sulfate and, thus multiple sulfate and chloride
ions were modeled to interpret additional electron density.
Structure comparison analysis revealed that a sulfate ion (e.g.,
SO4 304/A) in TgRPE occupies the binding site of a phosphate
moiety of substrate or product observed in the structure of the
human RPE enzyme (PDBs 3ovq and 3ovr) (Figure 4B). In all
ligand-bound human RPE structures, a loop (e.g., the β6–α5 loop
in TgRPE) supports position of a ligand at the active site, i.e.,
moves from its ligand-free conformation to cap a ligand bound to
the enzyme. Thus, similar loop movement is expected for TgRPE
upon binding of the substrate, i.e., a ligand. Apparently, binding
of SO2−4 sufficed the loop repositioning in TgRPE (Figure 4B).
Ribose 5-Phosphate Isomerase (RPI)
Crystal structure of a putative TgRPI was determined and
refined to 2.6 Å resolution with one protein molecule per
asymmetric unit (PDB 4nml; Figure 5A and Table 2). TgRPI
has a larger α/β/α sandwich catalytic domain (residues 1–127
and residues 225–259) with the Rossmann topology and a
smaller α/β sandwich oligomerization domain (residues 128–
224) (Figure 5A). Residues 180–186 between strand β8 and a 310-
helix (η3), Arg258, and Lys259 are absent in the structure due to
their disorder. BME was used in buffers during purification and
crystallization and is covalently linked to Cys82 in the structure.
One D-malate molecule and two chloride ions were modeled to
interpret additional electron density (Figures 5A,C). Applying
crystal symmetry operations PISA predicted that TgRPI might
exist as unstable dimer (BSA of ∼2,430 Å2) or stable dimer
(BSA of ∼3,340 Å2) in the crystal environment (Figure 5B).
Visualization of both dimers revealed that the first assembly is
held in place primarily by hydrogen-bonded interactions between
main-chain atoms of strand β13 of each monomer’s catalytic
domain (Figure 5B). The second dimer is stabilized by multiple
intramolecular contacts between residues from both TgRPI
domains. Homologous RPIs form similar stable dimers and, thus
stable TgRPI dimer may be considered biologically relevant.
PDBeFold identified several homologs of TgRPI, and we
used the crystal structure of RPI from Thermus thermophilus
(TtRPI; PDB 1uj6) (Hamada et al., 2003) determined in complex
with arabinose 5-phosphate to identify the active site of TgRPI
(Figure 5C). Both proteins share 45% sequence homology and
are superimposed with ∼1.0 Å r.m.s.d. over 218 Cα atoms. This
structural alignment revealed that D-malate and chloride ion
(e.g., CL 301/A) in TgRPI are bound in the protein’s active site,
mimicking parts of arabinose 5-phosphate in 1uj6 (Figure 5C).
D-malate makes hydrogen bonds with side chains of Lys8, Thr32,
and Thr33, and several van der Waals contacts with residues
of the phosphate-binding pocket of the active site (Schrödinger
SiteMap score 0.97). CL 301/A is bound in the oxyanion hole
of the active site and coordinated by main-chain nitrogen atoms
of Gly105 and Ala107, side chain carboxyl group of Glu111,
and two water molecules, HOH 415 and HOH 433 (Figure 5C).
The second chloride ion (e.g., CL 302/A) in TgRPI binds near
disordered residues 179–185 and makes bonds with main-chain
nitrogen atoms of Phe172 and Ile190, and the ε-amino group of
Lys154 (not shown).
The catalytic domain of homologous RPIs align well, while the
oligomerization domain has some distinct structural differences
among various species. For example, a peptide stretch between
residues Leu160 and Arg169 of the oligomerization domain
of TgRPI is longer than the equivalent region in TtRPI. In the
TgRPI, structure this segment is helix α6. We have found that
a similar helical element is present in E. coli RPI (Zhang et al.,
2003) (PDB 1o8b; 45% sequence homology; ∼1.4 Å r.m.s.d.
over 164 Cα atoms) and P. falciparum RPI (Holmes et al., 2006)
(PDB 2f8m; 45% sequence homology; ∼1.1 Å r.m.s.d. over 233
Cα atoms). Another example, strands β8 and β9 in TgRPI are
separated by a 310-helix (η3) and disordered residues 179–185,
while similar region in TtRPI, EcRPI, and PfRPI is shorter,
ordered, and extends toward the N-terminus of helix α4 of the
superimposed TgRPI. Thus, η3 and residues 179–185 seem to be
unique to TgRPI. Its length, proximity to the phosphate-binding
pocket, and potential flexibility suggest that it may participate in
the catalysis.
Ornithine Aminotransferase (OAT)
The crystal structure of TgOAT in complex with pyrodoxal-5′-
phosphate (PLP) was determined at 1.2 Å resolution (PDB 4nog;
Figure 6A and Table 2) and contains two protein chains in the
asymmetric unit (∼0.3 Å r.m.s.d. over 422 Cα atoms) that form a
well-studied functional dimer with BSA of∼5,770 Å2 (Shah et al.,
1997; Shen et al., 1998; Markova et al., 2005; Vedadi et al., 2007;
Jortzik et al., 2010) (Figure 6B). Each monomer has a mixed α/β
structural fold and consists of the cofactor PLP-binding domain
(residues 87–336), an N-terminal domain (residues 17–86),
and a C-terminal domain (residues 337–441) (Figure 6A). The
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PLP-binding domain comprises the eight-stranded central β-
sheet linked to 10 α-helices and 4 short α-helical segments. The
N- and C-terminal domain comprises three α-helices bounded
to a β-sheet of three and four β strands, respectively. The
difference between TgOATmonomers is observed at the position
of N-terminal α-helix and is likely affected by crystal packing.
BME used in the protein buffer solutions forms a covalent
bond to Cys353 in both TgOAT monomers. One 1,3,5-Tris(4-
carboxyphenyl)benzene (BTB), polyethylene glycol (PEG) and
acetate (ACT) molecule were modeled to interpret additional
electron density in chain B.
The dimerization interface is primarily formed between
residues of the PLP-binding and N-terminal domains of TgOAT.
The dimer is held by 3 salt bridges, Cys96–Cys96 disulfide
bond, 63 hydrogen bonds and 782 van der Waals interactions.
The TgOAT dimer bears structural similarities to homologous
enzymes from the aminotransferase class-III protein family
(Christen and Metzler, 1985; Mehta et al., 1993) and, thus,
may be considered biologically relevant. The list of homologous
structures with sequence identity >40% encloses structure of
OAT from human (r.m.s.d. ∼0.9 Å over 404 Cα atoms) (Shah
et al., 1997; Storici et al., 1999), OAT from P. falciparum (r.m.s.d.
∼1.2 Å over 384 Cα atoms) (Vedadi et al., 2007; Jortzik et al.,
2010) and OAT from P. yoelii (r.m.s.d. ∼1.0 Å over 369 Cα
atoms) (Vedadi et al., 2007). Among structures with similar
secondary structure fold and high r.m.s.d. value (∼1.9 Å over
395 Cα atoms) is the structure of GABA-OAT from E. coli
with sequence identity 31%. Recent reports indicate that TgOAT
shows a dual N-acetyl-ornithine (AcOrn) and γ-aminobutyric
acid (GABA) transaminase activity and may function in both
arginine and GABA metabolism (Astegno et al., 2017).
The cofactor-binding domain of TgOAT non-covalently binds
PLP molecule, i.e., PLP does not form the Schiff base with
conserve Lys286 (Figures 6A,C). Similarly to homologous OAT
structures obtained in complex with the cofactor (Shah et al.,
1997; Shen et al., 1998; Storici et al., 1999; Vedadi et al., 2007;
Jortzik et al., 2010), PLP interacts with Thr135, Gly136, Ala137,
Tyr171, Trp172, Glu224, Asp257, Ile259, Gln260, Lys286, Ser315,
and Thr316 (Figure 6C). Most of these residues are highly
conserved among TgOAT homologs and represent a viable,
“druggable” pocket (SiteMap score 1.03).
In vitro Studies of Targeted VivoPMO on
T. gondii Replication
HFFs were infected with YFP-expressing T. gondii tachyzoites
and treated with vivoPMOs targeted against all five enzymes
of interest. When treated at 10µM concentrations, each
morpholino resulted in approximately 50% reduction in
fluorescence in vitro (between 44% for PGM-targeted vivoPMO
to 56% reduction for OAT-targeted vivoPMO). This was
compared to the off-target, control morpholino, which resulted
in <10% fluorescence reduction. When compared statistically
using student T-test, levels of fluorescence in vitro were
statistically decreased (p < 0.05) when treating with targeted
vivoPMO relative to untreated fibroblasts infected with 2000
YFP-expressing tachyzoites as well as when compared to
infected cells treated with off-targetmorpholino. A representative
experiment showing these findings is in Figure 8A. Data
FIGURE 8 | (A) YFP/vivoPMO Efficacy Assay at 10µM. Targeted vivoPMOs
show statistically significant knockdown relative to off-target and to a
standardized parasite concentration as determined by student t-test. (B)
Wst-1 Cell Viability/ vivoPMO Toxicity Assay at 10µM. Targeted vivoPMOs do
not show statistically significantly (p < 0.05 by student T-test) different levels of
optical density relative to off-target vivoPMO or uninfected fibroblasts at 10µM
concentrations. (C) Ratio of On- to Off-Target vivoPMO for Replicate
Experiments Using 10µM of Targeted vivoPMO. The data presented here
represent five replicate experiments. Lower individual values suggest a larger
effect of the morpholino.
from all replicate experiments of the morpholino efficacy
assays, as well as statistical calculations and ratios reflecting
efficacy of targeted morpholino to off-target can be found in
Supplementary Table 1.
To confirm that these findings of decreased fluorescence
in vitro was not secondary to host-cell toxicity from the
vivoPMOs, a WST-1 assay was used. HFFs treated with
10µM concentrations of enzyme-targeted vivoPMOs were
statistically indistinguishable (p > 0.05) from untreated cells
by Student T-test. Toxicity was demonstrated at higher
vivoPMO concentrations of 20µM. A representative experiment
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demonstrating the absence of host-cell toxicity with vivoPMO
treatment at 10µM is in Figure 8B.
The ratio of targeted to off-target vivoPMO are displayed
in Figure 8C. This is shown for five replicate experiments
(Supplementary Table 1). This demonstrates that, in cultures
treated with on-target vivoPMO, parasitic replication was
reduced.
These findings were compared with the effect on tachyzoites
in a previously published full genome screen using CRISPR/Cas9
(Sidik et al., 2016). Three of the target proteins (TgPGM,
TgRPE, and TgRPI) that had a significantly reduced replication
phenotype in tachyzoites caused by vivoPMO knockdown
were found to contribute to parasite fitness when studied
using CRISPR/Cas9. The CRISPR/Cas9 data was annotated
and graphically presented in ToxoTB (http://toxodb.org/toxo).
TgPGM, TgRPE, and TgRPI show negative phenotypic/fitness
scores (−4.45,−0.31,−1.92, respectively) suggesting essentiality.
TgOAT appeared dispensable (fitness score of +1.2) in the
tachyzoite CRISPR/Cas9 assays consistent with TgOAT appeared
to be expressed predominantly in the oocyst stage (ToxoDB).
TgNDK (+2.45) also appeared to be dispensable in tachyzoites.
Immunofluorescence Assay
Recombinant protein for the five targets was also used to produce
antibodies in mice, which were used for immunostaining
to determine expression patterns within the parasite.
Immunolocalization was not successful with tachyzoites of
Toxoplasma for four of the five enzymes. For NDK, enzyme was
present in a granular pattern in the cytoplasm of tachyzoites,
located around the perimeter of the parasite and the posterior
part of the parasite. This can be seen in Figure 9.
DISCUSSION
The work characterized herein presents a detailed
characterization of enzyme structure that can be used
for modeling inhibitors of these targets and also presents
approaches for studying target phenotype with vivoPMO and
CRISPR/Cas9 which in combination develops a system to move
forward candidate targets (Figure 10). The targeted vivoPMOs
demonstrated statistically significant perturbation of parasitic
replication when compared to off-target morpholinos, without
concomitant host-cell toxicity, confirmed for some of these
with CRISPR/CAS9 screen. Inhibition of target enzymatic
function via small molecules or anti-sense might be a novel
therapeutic modality, should such small molecules exist.
Given the current limitations of anti-parasitic medicines for
the treatment of toxoplasmosis, new pharmacotherapy is of
significant interest. The multi-step approach, detailed here, of
in vitro inhibition through anti-sense techniques accompanied
by detailed structural characterization to identify possible
exploitable differences between host and parasite enzymes.
Confirmation by referring to a recently published CRISPR/Cas9-
based analysis, can also help to suggest importance of targets in
T. gondii tachyzoites (Sidik et al., 2016). This provides another
level of evidence that particular targets may be important for
the parasites replication. This approach was performed for
each of five enzymes identified as having potential biologic
importance and with favorable predicted druggability using
the TDR methodology. This favorable druggability was also
confirmed with in silico modeling using Schrödinger SiteMap,
which indicated each target demonstrated “druggable” pockets.
Each enzyme will be considered sequentially hereafter.
Phosphoglycerate mutase II, an enzyme at the core of
the glycolytic pathway, catalyzes the transition from 3-
phosphoglycerate to 2-phosphoglycerate, an important
preparatory step upstream of enolase and pyruvate kinase.
Although little work had been done on this Apicomplexan
enzyme as a potential drug target, we inferred that interrupting
glycolysis would prevent the production of pyruvate by
glycolysis, and thereby reduce input into the Kreb’s Cycle.
This, in turn, will reduce the number of electron carrying
compounds (NADH, FADH2), which would markedly reduce
ATP production. Interestingly, glycolysis has been targeted
successfully in other parasites, and also has been demonstrated
to have importance to host cell egress, as well as maintenance
of energy reserves when the parasite is found outside of host
cells (Ananvoranich et al., 2006; Fleige et al., 2007; Pomel et al.,
2008; Lin et al., 2011; Singh et al., 2013). These observations,
coupled with our own, are consistent with the observed effect
on parasite replication. It appears that putative inhibitors could
make this a robust tachyzoite molecular target with a compound
easily available to test. With the present crystal structure, further
structure-based molecular design approaches (such as virtual
screening) is possible given the favorable SiteMap score (0.98).
Nucleotide diphosphate kinase catalyzes the movement
of phosphate from a nucleoside triphosphate to a nucleoside
diphosphate (e.g., GTP + ADP –> GDP + ATP). Naturally,
disruption of this process could have an impact on the energy
economy within the parasite, as ATP would not be available
for important cellular tasks related to DNA replication and
the production of more parasites. Additionally, this is a stress
kinase, and thus its impact on the stressed organism (through
a tetracycline-dependent gene expression construct, RPS-13)
would be useful to explore. An immunofluorescence assay
revealed peripheral and posterior concentration of staining.
Interestingly, another intracellular pathogen, Leishmania
amazonensis, has been shown to secrete NDK to prevent
host-cell autolysis (Kolli et al., 2008). It would be of interest
to determine whether this enzyme plays a similar role in
Apicomplexans like T. gondii. Of note, NDK inhibition by
candidate compounds has been demonstrated to have efficacy
against certain species of Leishmania in vitro (Vieira et al.,
2015; Mishra et al., 2017). Crystal structure of TgNDK suggests
that the protein forms a hexamer with conserved nucleotide
binding sites. Pairwise structural alignment revealed that active
site of TgNDK may undergo similar conformational changes
as its closest homolog, humanNM23-H2 transcription factor
(Figure 3B). High structural homology to human transcription
factor (NM23-H2) in the residues in the catalytic site indicate
that selective inhibitors that do not act on human NM23-H2 will
be needed. Possible strategies that will facilitate such selectivity
include antisense, CRISPR, aptamer-based approaches where
the DNA/RNA sequences are divergent, among others. When
the dinucleotide is present in the active site, the residues in
both Tg and Hs structures have similar side chain orientations
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FIGURE 9 | Immunofluorescence Assay. This series of images depict the localization of nucleoside diphosphate kinase, one of the molecular targets herein discussed.
Note the concentration of red fluorescence at the periphery of the parasite. This is consistent with the localization of secreted proteins like Gra1, suggesting that NDK
could be secreted by the parasite. This has precedents in other pathogens, including M. tuberculosis and Leishmania.
FIGURE 10 | Summary figure showing the T. gondii drug discovery pipeline as described herein. The TDR Database provided important initial insights into potentially
important parasite proteins (Agüero et al., 2008; Magariños et al., 2012). Identification of proteins amenable to crystallographic analysis, solution of their structures,
abrogation with vivoPMO and confirmation of essentiality by querying the CRISPR/Cas9 database completed the pathway, identifying enriched targets with improved
therapeutic potential.
(Figure 3B), suggesting inhibitor selectivity between the species
might be difficult to achieve. On the other hand, when the
dinucleotide is absent, the active site loop comprising of
residues G59-F62 (Tg numbering) is shifted significantly (3–4
Å) between species. Additionally, TgNDK residue K60 is residue
R58 in the human ortholog, offering different hydrogen-bond
capacities to putative ligands. These observations suggest
opportunities for the selective design of TgNDK inhibitors
using structure-based molecular modeling techniques. Wang
et al. reported selective NM23-H2 (human ortholog) inhibitors
based on an isaindigotone scaffold (Wang et al., 2017). These
compounds were subjected to molecular docking studies and
were predicted to bind to the dinucleotide pocket. More so,
they offer an obvious starting point for biological evaluation in
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in vitro parasite models and the subsequent design of selective
TgNDK chemical probes/ligands.
The next two enzymes, due to their sequential placement
within the pentose-phosphate pathway, should be considered
together. Ribulose phosphate 3-epimerase functions in the
conversion of ribulose-5-phosphate into xylulose-5-phosphate,
which is a reaction in the Calvin cycle. It is just downstream
of the next target enzyme, ribose-5-phosphate isomerase, and
is important for the development of a pool of NADPH, as
well as in the pentose phosphate pathway that can convert
monosaccharides like glucose into nucleotide precursor pentose
sugars. This pathway has been of interest in targeting various
organisms, including P. falciparum and Trypanosoma cruzi
(Barrett, 1997; Bozdech and Ginsburg, 2005; Igoillo-Esteve et al.,
2007). The biology of RPE has proven to be of particular interest
in T. cruzi (Gonzalez et al., 2017). Indeed, the structure of RPE
had already been characterized in P. falciparum (Caruthers et al.,
2005). Determined crystal structure of TgRPE revealed that
Zn2+ binds in a putative active site. In addition, the presence
of SO2−4 in the active site induces the β6–α5 loop to move from
its presumed apo conformation in the absence of ligand, as
seen in the human RPE homolog, to holo conformation in the
ligand bound state (Figure 4B). Ribose-5-phosphate isomerase
is the enzyme in the pentose phosphate pathway just upstream
of ribulose phosphate 3-epimerase, and it has similar functions,
though it catalyzes the transition from ribose-5-phosphate to
ribulose-5-phosphate. It has been identified as a potential drug
target in P. falciparum, one of the causative agents of malaria,
due to its necessity in creating nucleotide precursors for DNA
synthesis and for maintaining a large pool of NADPH for rapid
replication and the metabolism necessary for the maintenance
thereof (Holmes et al., 2006). It has also been of interest and
targeted in Mycobacterium tuberculosis where inhibitors have
been identified (Roos et al., 2005). Additionally, this pathway
has been suggested as a drug target in trypanosomes, with
identified compounds and multiple mechanisms of inhibition
having been demonstrated, with current patents existing (de V.
C. Sinatti et al., 2017). Perhaps the most interesting feature of the
determined crystal structure of TgRPI is the disordered region
between residues 179–185 that comprises a part of what may
appear to be an active site loop. These residues and 310-helix
η3 are unique to TgRPI and might be important for catalysis
(Figure 5A).
Ornithine aminotransferase, the final enzyme considered
herein, is an enzyme involved in the urea cycle, TCA
cycle, polyamine synthesis, and other pathways. It catalyzes
a reversible reaction allowing interconversion of intermediates
from ornithine to amino acids. Other enzymes which act in this
pathway have been suggested as potential drug targets, and it
is critical for maintaining proper amounts of free amino acids,
so it was a good candidate for further study. Herein we found
a modest phenotype on replication but raised antibody did not
immunostain tachyzoites. Ornithine aminotransferase will be
studied further in the future to resolve some of these questions
and attempt to develop effective inhibitors, were it to prove
to be essential. Structural analysis reveals that TgOAT shares
similar structural folds to known OAT enzymes (Figure 6). We
have identified that TgOAT shares a conserved cofactor and
substrate-binding site with its closest homolog human GABA-
AT. To gain insights into function of TgOAT, we attempted
to crystallize this enzyme with several different inhibitors and
inactivators. As a result, three additional crystal structures of
TgOAT in complex with gabaculine (a potent inhibitor of human
GABA-AT) and (S)-4-amino-5-fluoropentanoic acid have been
determined (PDBs 5DJ9, 5E5I, and 5E3K). Therefore, we have
performed a full kinetic and structural analysis. The details of the
structure, substrate binding site, kinetic mechanism and function
of TgOAT will be described in our subsequent works.
Our approach described herein is a productive way to
identify molecular targets and could potentially be useful for
identifying small molecule inhibitors. In silico analysis of each
enzyme’s surface pockets/active sites suggest “druggable” areas
for binding of putative small molecules. The recent discovery
that CRISPR/Cas9 has future potential for treating HIV (Yin
et al., 2017) also raises the possibility that expression of simply
validated molecular targets can be eliminated by CRISPR/Cas9.
SiRNA is another possible therapeutic modality, and is being
studied in several infectious diseases, including Hepatitis C,
Ebola, and viral encephalitis, among others (Kumar et al., 2006;
Wan et al., 2014; Watanabe et al., 2014; Thi et al., 2015). As
our studies suggest, vivoPMO inhibited T. gondii replication;
antisense PMO is, therefore, another potential therapeutic
modality that might effectively treat parasitic infection. The
data presented in Figure 8 and CRISPR/Cas9 screen suggest
a phenotype for TgPGM, TgRPE, and TgRPI, but do not
yet prove the targets are essential. With confirmation in the
future, vivoPMO-based therapy with a less toxic molecular
transporter has promise. The safety of PMO is well-documented
in several clinical trials in treating genetic, cardiovascular, and
infectious diseases including Duchenne muscular dystrophy
(DMD), restenosis, and Marburg and Ebola hemorrhagic fevers
(Kipshidze et al., 2007; Kinali et al., 2009; Cirak et al., 2011;
Heald et al., 2014). It has even shown efficacy against a relative
of T. gondii, the causative agent of malaria, P. falciparum
(Augagneur et al., 2012). Eteplirsen (ExonDys51) is an FDA-
approved PMO drug for treatment of DMD in patients who have
confirmed mutation of the DMD gene that is amenable to exon
51 skipping. A clinical trial is underway using a cell-penetrating
peptide conjugated eteplirsen (the PPMO technology) to increase
intracellular delivery of eteplirsen for greater efficacy, lower
dose and less frequent dosing (clincialtrials.gov: NCT03375255).
With the advent of novel modalities, including antisense and
small molecule inhibition, for the treatment of both active and
latent infection, it may be possible to eradicate human T. gondii
infection, and the successes achieved by physicians and scientists
in combatting smallpox and dracunculiasis might extend to
toxoplasmosis as well.
ETHICS STATEMENT
This study was carried out in accordance with the
recommendations of The Home Office of the UK Government
under the Animals [Scientific Procedures] Act 1986. All work
was covered by License PPL60/4568, Treatment and Prevention
of Toxoplasmosis with approval by the University of Strathclyde
ethical review board.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 17 October 2018 | Volume 8 | Article 352
Lykins et al. Therapeutic Target Characterization for Toxoplasmosis
AUTHOR CONTRIBUTIONS
1JL, HN, and RM: Conceptualization. JL, HN, EF, AH, GM, YZ,
ID, KF, LS, JR, KE, SD, CR, SW, MM, SM, CF, ES, RM, and WA:
Data curation. JL, EF, AH, GM, YZ, and RM: Formal analysis.
CR, RM, and WA: Funding acquisition. JL, HN, EF, AH, GM,
YZ, ID, KF, LS, JR, KE, SD, CR, SW, MM, SM, CF, ES, RM, and
WA: Investigation. JL, HN, EF, AH, GM, YZ, ID, KF, LS, JR,
KE, SD, CR, SW, JM, HM, MM, SM, CF, ES, DS, DR, RM, and
WA: Methodology. RM and WA: Project administration. CR,
RM, and WA: Resources. RM and WA: Supervision. JL, EF, AH,
GM, YZ, RM, and WA: Validation. JL, EF, AH, GM, YZ, and KE:
Visualization. JL, EF, AH, GM, and RM: Writing-original draft.
JL, HN, EF, AH, GM, YZ, ID, KF, LS, JR, KE, SD, CR, SW, JM,
HM, MM, SM, CF, ES, DS, DR, RM, and WA: Writing-review
and editing.
ACKNOWLEDGMENTS
This research was supported in part by the NIH NIDDK
grant #2T35DK062719-27. The data collection was performed
at the LS-CAT Sector 21 at the Advanced Photon Source
supported by the Argonne National Laboratory operated
by the University of Chicago Argonne, LLC, for the U.S.
Department of Energy, Office of Biological and Environmental
Research under contract DE-AC02-06CH11357. The LS-
CAT is supported by the Michigan Economic Development
Corporation and the Michigan Technology Tri-Corridor
(Grant 085P1000817). This work has been funded by NIAID,
NIH, Department of HHS, under Contracts No. HHSN
272200700058C, HHSN272201200026C, and HHSN2722017
00060C (WA).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fcimb.
2018.00352/full#supplementary-material
Supplementary Table 1 | Data from replicate experiments demonstrate the
efficacy of target-specific morpholino on parasite replication in vitro. Ratios of
target-specific to off-target morpholino for all targets reflect statistically significant
perturbation of parasite replication.
REFERENCES
Agüero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F. S., Campbell, R.
K., et al. (2008). Genomic-scale prioritization of drug targets: the TDR Targets
database. Nat. Rev. Drug Discov. 7, 900–907. doi: 10.1038/nrd2684
Akana, J., Fedorov, A. A., Fedorov, E., Novak, W. R. P., Babbitt, P. C., Almo, S. C.,
et al. (2006). D-Ribulose 5-phosphate 3-epimerase: functional and structural
relationships to members of the ribulose-phosphate binding (beta/alpha)8-
barrel superfamily. Biochemistry 45, 2493–2503. doi: 10.1021/bi052474m
Ananvoranich, S., Al Rayes, M., Al Riyahi, A., andWang, X. (2006). RNA silencing
of glycolysis pathway in Toxoplasma gondii. J. Eukaryot. Microbiol. 53(Suppl.
1), S162–S163. doi: 10.1111/j.1550-7408.2006.00216.x
Anderson, W. F. (2009). Structural genomics and drug discovery for infectious
diseases. Infect. Disord. 9, 507–517. doi: 10.2174/187152609789105713
Aslanidis, C., and de Jong, P. J. (1990). Ligation-independent cloning
of PCR products (LIC-PCR). Nucleic Acids Res. 18, 6069–6074.
doi: 10.1093/nar/18.20.6069
Astegno, A., Maresi, E., Bertoldi, M., Verde, V. L., Paiardini, A., and
Dominici, P. (2017). Unique substrate specificity of ornithine aminotransferase
from Toxoplasma gondii. Biochem. J. 474, 939–955. doi: 10.1042/BCJ201
61021
Augagneur, Y., Wesolowski, D., Tae, H. S., Altman, S., and Mamoun, C.
B. (2012). Gene selective mRNA cleavage inhibits the development of
Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 109, 6235–6240.
doi: 10.1073/pnas.1203516109
Barrett, M. P. (1997). The pentose phosphate pathway and parasitic protozoa.
Parasitol. Today 13, 11–16. doi: 10.1016/S0169-4758(96)10075-2
Berman, H. M., Bhat, T. N., Bourne, P. E., Feng, Z., Gilliland, G., Weissig, H., et al.
(2000). The protein data bank and the challenge of structural genomics. Nat.
Struct. Mol. Biol. 7, 957–959. doi: 10.1038/80734
Bozdech, Z., and Ginsburg, H. (2005). Data mining of the transcriptome
of Plasmodium falciparum: the pentose phosphate pathway and ancillary
processes.Malar. J. 4:17. doi: 10.1186/1475-2875-4-17
Caruthers, J., Bosch, J., Buckner, F., Van Voorhis, W., Myler, P., Worthey,
E., et al. (2005). Structure of a ribulose 5-phosphate 3-epimerase from
Plasmodium falciparum. Proteins Struct. Funct. Bioinforma. 62, 338–342.
doi: 10.1002/prot.20764
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R.
M., Kapral, G. J., et al. (2010). MolProbity: all-atom structure validation
for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66,
12–21. doi: 10.1107/S0907444909042073
Chevalier, N., Rigden, D. J., Van Roy, J., Opperdoes, F. R., and Michels,
P. A. (2000). Trypanosoma brucei contains a 2,3-bisphosphoglycerate
independent phosphoglycerate mutase. Eur. J. Biochem. FEBS 267, 1464–1472.
doi: 10.1046/j.1432-1327.2000.01145.x
Christen, P., and Metzler, D. E. (1985). Transaminases. New York, NY: Wiley.
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony,
K., et al. (2011). Exon skipping and dystrophin restoration in patients
with Duchenne muscular dystrophy after systemic phosphorodiamidate
morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
Lancet 378, 595–605. doi: 10.1016/S0140-6736(11)60756-3
Crowther, G. J., Shanmugam, D., Carmona, S. J., Doyle, M. A., Hertz-Fowler, C.,
Berriman,M., et al. (2010). Identification of attractive drug targets in neglected-
disease pathogens using an in silico approach. PLoS Negl. Trop. Dis. 4:e804.
doi: 10.1371/journal.pntd.0000804
Davies, D. R., Staker, B. L., Abendroth, J. A., Edwards, T. E., Hartley, R.,
Leonard, J., et al. (2011). An ensemble of structures of Burkholderia
pseudomallei 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase.
Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 67, 1044–1050.
doi: 10.1107/S1744309111030405
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., et al.
(2007). MolProbity: all-atom contacts and structure validation for proteins and
nucleic acids. Nucleic Acids Res. 35, W375–W383. doi: 10.1093/nar/gkm216
de Beer, T. A., Berka, K., Thornton, J. M., and Laskowski, R. A. (2014). PDBsum
additions. Nucleic Acids Res. 42, D292–D296. doi: 10.1093/nar/gkt940
de V. C. Sinatti, V., R Baptista, L. P., Alves-Ferreira, M., Dardenne, L., Hermínio
Martins da Silva, J., and Guimarães, A. C. (2017). In silico identification of
inhibitors of ribose 5-phosphate isomerase from Trypanosoma cruzi using
ligand and structure based approaches. J. Mol. Graph. Model. 77, 168–180.
doi: 10.1016/j.jmgm.2017.08.007
Dexheimer, T. S., Carey, S. S., Zuohe, S., Gokhale, V. M., Hu, X., Murata, L. B., et al.
(2009). NM23-H2 may play an indirect role in transcriptional activation of c-
myc gene expression but does not cleave the nuclease hypersensitive element
III1.Mol. Cancer Ther. 8, 1363–1377. doi: 10.2210/pdb3bbb/pdb
Djikeng, A., Raverdy, S., Foster, J., Bartholomeu, D., Zhang, Y., El-Sayed, N. M.,
et al. (2007). Cofactor-independent phosphoglycerate mutase is an essential
gene in procyclic form Trypanosoma brucei. Parasitol. Res. 100, 887–892.
doi: 10.1007/s00436-006-0332-7
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 18 October 2018 | Volume 8 | Article 352
Lykins et al. Therapeutic Target Characterization for Toxoplasmosis
Dranow, D. M., Conrady, D. G., Lorimer, D. D., and Edwards, T. E. (2017). Crystal
Structure of a ribulose-phosphate 3-epimerase fromNeisseria gonorrhoeaewith
bound phosphate. BE Publ. doi: 10.2210/pdb5umf/pdb
Dubey, R., Staker, B. L., Foe, I. T., Bogyo, M., Myler, P. J., Ngô, H. M.,
et al. (2017). Membrane skeletal association and post-translational allosteric
regulation of Toxoplasma gondii GAPDH1. Mol. Microbiol. 103, 618–634.
doi: 10.1111/mmi.13577
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for
molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132.
doi: 10.1107/S0907444904019158
Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010). Features and
development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501.
doi: 10.1107/S0907444910007493
Flegr, J., Prandota, J., Sovicˇková, M., and Israili, Z. H. (2014). Toxoplasmosis – A
Global Threat. Correlation of latent toxoplasmosis with specific disease burden
in a set of 88 countries. PLoS ONE 9:e90203. doi: 10.1371/journal.pone.0090203
Fleige, T., Fischer, K., Ferguson, D. J. P., Gross, U., and Bohne, W.
(2007). Carbohydrate metabolism in the Toxoplasma gondii apicoplast:
localization of three glycolytic isoenzymes, the single pyruvate dehydrogenase
complex, and a plastid phosphate translocator. Eukaryot. Cell 6, 984–996.
doi: 10.1128/EC.00061-07
Furtado, J. M., Smith, J. R., Belfort, R., Gattey, D., and Winthrop, K. L.
(2011). Toxoplasmosis: a global threat. J. Glob. Infect. Dis. 3, 281–284.
doi: 10.4103/0974-777X.83536
Gonzalez, S. N., Valsecchi, W. M., Maugeri, D., Delfino, J. M., and Cazzulo, J. J.
(2017). Structure, kinetic characterization and subcellular localization of the
two ribulose 5-phosphate epimerase isoenzymes fromTrypanosoma cruzi. PLoS
ONE 12:e0172405. doi: 10.1371/journal.pone.0172405
Halgren, T. (2007). New method for fast and accurate binding-site
identification and analysis. Chem. Biol. Drug Des. 69, 146–148.
doi: 10.1111/j.1747-0285.2007.00483.x
Hamada, K., Ago, H., Sugahara, M., Nodake, Y., Kuramitsu, S., and Miyano,
M. (2003). Oxyanion hole-stabilized stereospecific isomerization in
ribose-5-phosphate isomerase (Rpi). J. Biol. Chem. 278, 49183–49190.
doi: 10.1074/jbc.M309272200
Hasegawa, H., and Holm, L. (2009). Advances and pitfalls of protein structural
alignment. Curr. Opin. Struct. Biol. 19, 341–348. doi: 10.1016/j.sbi.2009.04.003
Heald, A. E., Iversen, P. L., Saoud, J. B., Sazani, P., Charleston, J. S., Axtelle,
T., et al. (2014). Safety and pharmacokinetic profiles of phosphorodiamidate
morpholino oligomers with activity against ebola virus and marburg virus:
results of two single ascending dose studies. Antimicrob. Agents Chemother. 58,
6639–47.. doi: 10.1128/AAC.03442-14
Holmes, M. A., Buckner, F. S., Van Voorhis, W. C., Verlinde, C. L. M. J., Mehlin,
C., Boni, E., et al. (2006). Structure of ribose 5-phosphate isomerase from
Plasmodium falciparum. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.
62, 427–431. doi: 10.1107/S1744309106010876
Igoillo-Esteve, M., Maugeri, D., Stern, A. L., Beluardi, P., and Cazzulo, J. J. (2007).
The pentose phosphate pathway in Trypanosoma cruzi: a potential target for
the chemotherapy of Chagas disease. An. Acad. Bras. Ciênc. 79, 649–663.
doi: 10.1590/S0001-37652007000400007
Jelakovic, S., Kopriva, S., Süss, K.-H., and Schulz, G. E. (2003). Structure and
catalytic mechanism of the cytosolic d-ribulose-5-phosphate 3-epimerase from
rice. J. Mol. Biol. 326, 127–135. doi: 10.1016/S0022-2836(02)01374-8
Joint Center for Structural Genomics (2011). Crystal Structure of a D-
ribulose-5-phosphate-3-epimerase (NP_954699) from HOMO SAPIENS at
2.20 A Resolution. Available online at: http://www.rcsb.org/pdb/explore.do?
structureId=3qc3
Jortzik, E., Fritz-Wolf, K., Sturm, N., Hipp, M., Rahlfs, S., and Becker, K. (2010).
Redox regulation of Plasmodium falciparum ornithine δ-aminotransferase. J.
Mol. Biol. 402, 445–459. doi: 10.1016/j.jmb.2010.07.039
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C.,
et al. (2009). Local restoration of dystrophin expression with the morpholino
oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-
controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918–928.
doi: 10.1016/S1474-4422(09)70211-X
Kipshidze, N., Iversen, P., Overlie, P., Dunlap, T., Titus, B., Lee, D., et al. (2007).
First human experience with local delivery of novel antisense AVI-4126 with
Infiltrator catheter in de novo native and restenotic coronary arteries: 6-month
clinical and angiographic follow-up from AVAIL study. Cardiovasc. Revasc.
Med. Mol. Interv. 8, 230–235. doi: 10.1016/j.carrev.2007.04.002
Kito, K., Sanada, Y., and Katunuma, N. (1978). Mode of inhibition of ornithine
aminotransferase by L-canaline. J. Biochem. 83, 201–206.
Kolli, B. K., Kostal, J., Zaborina, O., Chakrabarty, A. M., and Chang, K.-P.
(2008). Leishmania-released nucleoside diphosphate kinase prevents ATP-
mediated cytolysis of macrophages. Mol. Biochem. Parasitol. 158, 163–175.
doi: 10.1016/j.molbiopara.2007.12.010
Kopp, J., Kopriva, S., Süss, K. H., and Schulz, G. E. (1999). Structure
and mechanism of the amphibolic enzyme D-ribulose-5-phosphate
3-epimerase from potato chloroplasts. J. Mol. Biol. 287, 761–771.
doi: 10.1006/jmbi.1999.2643
Krissinel, E. (2009). Crystal contacts as nature’s docking solutions. J. Comput.
Chem. 31, 133–143. doi: 10.1002/jcc.21303
Krissinel, E., and Henrick, K. (2004). Secondary-structure matching (SSM), a new
tool for fast protein structure alignment in three dimensions. Acta Crystallogr.
D Biol. Crystallogr. 60, 2256–2268. doi: 10.1107/S0907444904026460
Krissinel, E., and Henrick, K. (2005). “Detection of protein assemblies in crystals,”
in Computational Life Sciences Lecture Notes in Computer Science, eds M. R.
Berthold, R. C. Glen, K. Diederichs, O. Kohlbacher, and I. Fischer (Berlin;
Heidelberg: Springer), 163–174.
Krissinel, E., andHenrick, K. (2007). Inference of macromolecular assemblies from
crystalline state. J. Mol. Biol. 372, 774–797. doi: 10.1016/j.jmb.2007.05.022
Kronenberger, T., Lindner, J., Meissner, K. A., Zimbres, F. M., Coronado, M.
A., Sauer, F. M., et al. (2014). Vitamin B6-dependent enzymes in the human
malaria parasite Plasmodium falciparum: a druggable target? BioMed Res. Int.
2014:108516. doi: 10.1155/2014/108516
Kumar, P., Lee, S. K., Shankar, P., and Manjunath, N. (2006). A single siRNA
suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med.
3:e96. doi: 10.1371/journal.pmed.0030096
Lai, B.-S., Witola, W. H., Bissati, K. E., Zhou, Y., Mui, E., Fomovska, A.,
et al. (2012). Molecular target validation, antimicrobial delivery, and potential
treatment of Toxoplasma gondii infections. Proc. Natl. Acad. Sci. U.S.A. 109,
14182–7. doi: 10.1073/pnas.1208775109
Lam, S. D., Dawson, N. L., Das, S., Sillitoe, I., Ashford, P., Lee, D., et al. (2016).
Gene3D: expanding the utility of domain assignments. Nucleic Acids Res. 44,
D404–409. doi: 10.1093/nar/gkv1231
Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993).
PROCHECK: a program to check the stereochemical quality of protein
structures. J. Appl. Crystallogr. 26, 283–291.
Li, X., Tang, S., Wang, Q.-Q., Leung, E. L.-H., Jin, H., Huang, Y., et al. (2017).
Identification of epigallocatechin-3- gallate as an inhibitor of phosphoglycerate
mutase 1. Front. Pharmacol. 8:325. doi: 10.3389/fphar.2017.00325
Liang, W., Ouyang, S., Shaw, N., Joachimiak, A., Zhang, R., and Liu, Z.-J. (2011).
Conversion of D-ribulose 5-phosphate to D-xylulose 5-phosphate: new insights
from structural and biochemical studies on human RPE. FASEB J. 25, 497–504.
doi: 10.1096/fj.10-171207
Lin, S. S., Blume, M., von Ahsen, N., Gross, U., and Bohne,W. (2011). Extracellular
Toxoplasma gondii tachyzoites do not require carbon source uptake for ATP
maintenance, glidingmotility and invasion in the first hour of their extracellular
life. Int. J. Parasitol. 41, 835–841. doi: 10.1016/j.ijpara.2011.03.005
Lipinski, C. A. (2004). Lead- and drug-like compounds: the rule-of-five
revolution. Drug Discov. Today Technol. 1, 337–341. doi: 10.1016/j.ddtec.2004.
11.007
Liu, Y., Huang, R., Han, L., Ke, W., Shao, K., Ye, L., et al. (2009). Brain-
targeting gene delivery and cellular internalization mechanisms for modified
rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30, 4195–4202.
doi: 10.1016/j.biomaterials.2009.02.051
Lykins, J., Wang, K., Wheeler, K., Clouser, F., Dixon, A., Bissati, K. E., et al. (2016).
Understanding toxoplasmosis in the united states through “large data” analyses.
Clin. Infect. Dis. 63, 468–475. doi: 10.1093/cid/ciw356
Magariños, M. P., Carmona, S. J., Crowther, G. J., Ralph, S. A., Roos,
D. S., Shanmugam, D., et al. (2012). TDR Targets: a chemogenomics
resource for neglected diseases. Nucleic Acids Res. 40, D1118–D1127.
doi: 10.1093/nar/gkr1053
Markova, M., Peneff, C., Hewlins, M. J. E., Schirmer, T., and John, R. A. (2005).
Determinants of substrate specificity in ω-aminotransferases. J. Biol. Chem.
280, 36409–36416. doi: 10.1074/jbc.M506977200
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 19 October 2018 | Volume 8 | Article 352
Lykins et al. Therapeutic Target Characterization for Toxoplasmosis
McAleese, S. M., Fothergill-Gilmore, L. A., and Dixon, H. B. (1985). The
phosphonomethyl analogue of 3-phosphoglycerate is a potent competitive
inhibitor of phosphoglycerate mutases. Biochem. J. 230, 535–542.
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C.,
and Read, R. J. (2007). Phaser crystallographic software. J. Appl. Crystallogr. 40,
658–674. doi: 10.1107/S0021889807021206
McLeod, R., Boyer, K. M., Lee, D., Mui, E., Wroblewski, K., Karrison, T., et al.
(2012). Prematurity and severity are associated with Toxoplasma gondii alleles
(NCCCTS, 1981-2009). Clin. Infect. Dis. 54, 1595–1605. doi: 10.1093/cid/cis258
McLeod, R., Lai, B. S., Witola, W., Bissati, K. E., Mui, E., Moulton, H., et al. (2013).
Conjugate Constructs, Delivery, and Use for Treatment of Disease. Available
online at: http://www.google.com/patents/US8575126 (Accessed May 8, 2017).
McLeod, R., Lykins, J., Noble, A. G., Rabiah, P., Swisher, C. N., Heydemann, P. T.,
et al. (2014). Management of congenital toxoplasmosis. Curr. Pediatr. Rep. 2,
166–194. doi: 10.1007/s40124-014-0055-7
McPhillie, M., Zhou, Y., El Bissatai, K., Dubey, J., Lorenzi, H., Capper, M.,
et al. (2016). New paradigms for understanding and step changes in treating
active and chronic, persistent apicomplexan infections. Sci. Rep. 6:29179.
doi: 10.1038/srep29179
Mehta, P. K., Hale, T. I., and Christen, P. (1993). Aminotransferases:
demonstration of homology and division into evolutionary subgroups. Eur. J.
Biochem. 214, 549–561. doi: 10.1111/j.1432-1033.1993.tb17953.x
Min, K., Song, H. K., Chang, C., Kim, S. Y., Lee, K.-J., and Suh, S.W. (2002). Crystal
structure of human nucleoside diphosphate kinase A, a metastasis suppressor.
Proteins Struct. Funct. Bioinform. 46, 340–342. doi: 10.1002/prot.10038
Minor, W., Cymborowski, M., Otwinowski, Z., and Chruszcz, M. (2006). HKL-
3000: the integration of data reduction and structure solution – from diffraction
images to an initial model in minutes. Acta Crystallogr. D Biol. Crystallogr. 62,
859–866. doi: 10.1107/S0907444906019949
Mishra, A. K., Singh, N., Agnihotri, P., Mishra, S., Singh, S. P., Kolli, B. K., et al.
(2017). Discovery of novel inhibitors for Leishmania nucleoside diphosphatase
kinase (NDK) based on its structural and functional characterization.
J. Comput. Aided Mol. Des. 31, 547–562. doi: 10.1007/s10822-017-
0022-9
Montoya, J. G., and Liesenfeld, O. (2004). Toxoplasmosis. Lancet 363, 1965–1976.
doi: 10.1016/S0140-6736(04)16412-X
Morris, R. J., Perrakis, A., and Lamzin, V. S. (2003). “ARP/wARP and automatic
interpretation of protein electron density maps,” in Macromolecular
Crystallography, Part D., ed. B.-M. Enzymology (Academic Press), 229–244.
Available online at: http://www.sciencedirect.com/science/article/pii/
S0076687903740117 (Accessed May 5, 2017).
Motomura, K., Hirota, R., Okada, M., Ikeda, T., Ishida, T., and Kuroda,
A. (2014). A new subfamily of polyphosphate kinase 2 (Class III PPK2)
catalyzes both nucleoside monophosphate phosphorylation and nucleoside
diphosphate phosphorylation. Appl. Environ. Microbiol. 80, 2602–2608.
doi: 10.1128/AEM.03971-13
Müller, I. B., Wu, F., Bergmann, B., Knöckel, J., Walter, R. D., Gehring, H., et al.
(2009). Poisoning pyridoxal 5-phosphate-dependent enzymes: a new strategy
to target the malaria parasite Plasmodium falciparum. PLoS ONE 4:e4406.
doi: 10.1371/journal.pone.0004406
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R.
A., Nicholls, R. A., et al. (2011). REFMAC5 for the refinement of
macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67,
355–367. doi: 10.1107/S0907444911001314
Ngô, H. M., Zhou, Y., Lorenzi, H., Wang, K., Kim, T.-K., Zhou,
Y., et al. (2017). Toxoplasma modulates signature pathways of
human epilepsy, neurodegeneration & cancer. Sci. Rep. 7:11496.
doi: 10.1038/s41598-017-10675-6
Opperdoes, F. R., and Michels, P. A. (2001). Enzymes of carbohydrate
metabolism as potential drug targets. Int. J. Parasitol. 31, 482–490.
doi: 10.1016/S0020-7519(01)00155-2
Pomel, S., Luk, F. C. Y., and Beckers, C. J. M. (2008). Host cell egress and
invasion inducemarked relocations of glycolytic enzymes in Toxoplasma gondii
tachyzoites. PLoS Pathog 4:e1000188. doi: 10.1371/journal.ppat.1000188
Reyes, P., Rathod, P. K., Sanchez, D. J., Mrema, J. E., Rieckmann, K. H., and
Heidrich, H. G. (1982). Enzymes of purine and pyrimidine metabolism from
the human malaria parasite, Plasmodium falciparum. Mol. Biochem. Parasitol.
5, 275–290.
Rigden, D. J., Walter, R. A., Phillips, S. E. V., and Fothergill-Gilmore, L. A. (1999).
Polyanionic inhibitors of phosphoglycerate mutase: combined structural and
biochemical analysis. J. Mol. Biol. 289, 691–699. doi: 10.1006/jmbi.1999.2848
Roos, A. K., Burgos, E., Ericsson, D. J., Salmon, L., and Mowbray, S. L. (2005).
Competitive inhibitors of Mycobacterium tuberculosis ribose-5-phosphate
isomerase B reveal new information about the reaction mechanism. J. Biol.
Chem. 280, 6416–6422. doi: 10.1074/jbc.M412018200
Ruan, J., Mouveaux, T., Light, S. H., Minasov, G., Anderson, W. F., Tomavo, S.,
et al. (2015). The structure of bradyzoite-specific enolase from Toxoplasma
gondii reveals insights into its dual cytoplasmic and nuclear functions. Acta
Crystallogr. D Biol. Crystallogr. 71, 417–426. doi: 10.1107/S1399004714026479
Samuel, B. U., Hearn, B., Mack, D., Wender, P., Rothbard, J., Kirisits, M. J., et al.
(2003). Delivery of antimicrobials into parasites. Proc. Natl. Acad. Sci. U.S.A.
100, 14281–14286. doi: 10.1073/pnas.2436169100
Schneider, B., Xu, Y. W., Janin, J., Véron, M., and Deville-Bonne, D.
(1998). 3′-Phosphorylated nucleotides are tight binding inhibitors of
nucleoside diphosphate kinase activity. J. Biol. Chem. 273, 28773–28778.
doi: 10.1074/jbc.273.44.28773
Schrödinger Release 2015-3. (2018). Small-Molecule Drug Discovery Suite 2018-3.
New York, NY: Schrödinger, LLC.
Shah, S. A., Shen, B. W., and Brünger, A. T. (1997). Human ornithine
aminotransferase complexed with L-canaline and gabaculine:
structural basis for substrate recognition. Structure 5, 1067–1075.
doi: 10.1016/S0969-2126(97)00258-X
Shen, B. W., Hennig, M., Hohenester, E., Jansonius, J. N., and Schirmer, T. (1998).
Crystal structure of human recombinant ornithine aminotransferase. J. Mol.
Biol. 277, 81–102. doi: 10.1006/jmbi.1997.1583
Sidik, S. M., Huet, D., Ganesan, S. M., Huynh, M.-H., Wang, T., Nasamu, A. S.,
et al. (2016). A genome-wide CRISPR screen in toxoplasma identifies essential
apicomplexan genes. Cell 166, 1423–1435.e12. doi: 10.1016/j.cell.2016.08.019
Sillitoe, I., Lewis, T. E., Cuff, A., Das, S., Ashford, P., Dawson, N. L., et al. (2015).
CATH: comprehensive structural and functional annotations for genome
sequences. Nucleic Acids Res. 43, D376–D381. doi: 10.1093/nar/gku947
Singh, P. K., Kushwaha, S., Mohd, S., Pathak, M., and Misra-Bhattacharya,
S. (2013). in vitro gene silencing of independent phosphoglycerate mutase
(iPGM) in the filarial parasite Brugia malayi. Infect. Dis. Poverty 2:5.
doi: 10.1186/2049-9957-2-5
Slabinski, L., Jaroszewski, L., Rychlewski, L.,Wilson, I. A., Lesley, S. A., and Godzik,
A. (2007). XtalPred: a web server for prediction of protein crystallizability.
Bioinform. Oxf. Engl. 23, 3403–3405. doi: 10.1093/bioinformatics/btm477
Storici, P., Capitani, G., Müller, R., Schirmer, T., and Jansonius, J. N. (1999).
Crystal structure of human ornithine aminotransferase complexed with the
highly specific and potent inhibitor 5-fluoromethylornithine11. J. Mol. Biol.
285, 297–309. doi: 10.1006/jmbi.1998.2289
Sturm, N., Jortzik, E., Mailu, B. M., Koncarevic, S., Deponte, M., Forchhammer,
K., et al. (2009). Identification of proteins targeted by the thioredoxin
superfamily in Plasmodium falciparum. PLoS Pathog. 5:e1000383.
doi: 10.1371/journal.ppat.1000383
Thi, E. P., Mire, C. E., Lee, A. C. H., Geisbert, J. B., Zhou, J. Z., Agans, K. N., et al.
(2015). Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected
nonhuman primates. Nature 521, 362–365. doi: 10.1038/nature14442
Tonkin, M. L., Halavaty, A. S., Ramaswamy, R., Ruan, J., Igarashi, M., Ngô, H.
M., et al. (2015). Structural and functional divergence of the aldolase fold in
Toxoplasma gondii. J. Mol. Biol. 427, 840–852. doi: 10.1016/j.jmb.2014.09.019
Torgerson, P. R., and Mastroiacovo, P. (2013). The global burden of congenital
toxoplasmosis: a systematic review. Bull. World Health Organ. 91, 501–508.
doi: 10.2471/BLT.12.111732
Vedadi, M., Lew, J., Artz, J., Amani, M., Zhao, Y., Dong, A., et al. (2007). Genome-
scale protein expression and structural biology of Plasmodium falciparum
and related Apicomplexan organisms. Mol. Biochem. Parasitol. 151, 100–110.
doi: 10.1016/j.molbiopara.2006.10.011
Vieira, P. S., de Giuseppe, P. O., Murakami, M. T., and de Oliveira, A. H. C.
(2015). Crystal structure and biophysical characterization of the nucleoside
diphosphate kinase from Leishmania braziliensis. BMC Struct. Biol. 15:2.
doi: 10.1186/s12900-015-0030-8
Wan, C., Allen, T. M., and Cullis, P. R. (2014). Lipid nanoparticle delivery
systems for siRNA-based therapeutics. Drug Deliv. Transl. Res. 4, 74–83.
doi: 10.1007/s13346-013-0161-z
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 20 October 2018 | Volume 8 | Article 352
Lykins et al. Therapeutic Target Characterization for Toxoplasmosis
Wang, P., Jiang, L., Cao, Y., Zhang, X., Chen, B., Zhang, S., et al. (2018).
Xanthone derivatives as phosphoglycerate mutase 1 inhibitors: design,
synthesis, and biological evaluation. Bioorg. Med. Chem. 26, 1961–1970.
doi: 10.1016/j.bmc.2018.02.044
Wang, Y.-Q., Huang, Z.-L., Chen, S.-B., Wang, C.-X., Shan, C., Yin, Q.-K., et al.
(2017). Design, synthesis, and evaluation of new selective NM23-H2 binders as
c-MYC transcription inhibitors via disruption of the NM23-H2/G-quadruplex
interaction. J. Med. Chem. 60, 6924–6941. doi: 10.1021/acs.jmedchem.7b00421
Watanabe, T., Hatakeyama, H., Matsuda-Yasui, C., Sato, Y., Sudoh, M., Takagi, A.,
et al. (2014). in vivo therapeutic potential of Dicer-hunting siRNAs targeting
infectious hepatitis C virus. Sci. Rep. 4:4750. doi: 10.1038/srep04750
Williamson, W. T., and Wood, W. A. (1966). “[108] d-Ribulose 5-phosphate 3-
epimerase,” inMethods in Enzymology Carbohydrate Metabolism, ed W. Wood
(East Lansing: Academic Press), 605–608. Available online at: http://www.
sciencedirect.com/science/article/pii/0076687966091225
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P.
R., et al. (2011). Overview of the CCP4 suite and current developments. Acta
Crystallogr. D Biol. Crystallogr. 67, 235–242. doi: 10.1107/S0907444910045749
Wise, E. L., Akana, J., Gerlt, J. A., and Rayment, I. (2004). Structure of d-ribulose 5-
phosphate 3-epimerase from synechocystis to 1.6 Å resolution.Acta Crystallogr.
D Biol. Crystallogr. 60, 1687–1690. doi: 10.1107/S0907444904015896
Wood, T. (1979). Purification and properties of d-ribulose-5-phosphate
3-epimerase from calf liver. Biochim. Biophys. Acta 570, 352–362.
doi: 10.1016/0005-2744(79)90155-4
Yin, C., Zhang, T., Qu, X., Zhang, Y., Putatunda, R., Xiao, X., et al. (2017). in vivo
excision of HIV-1 provirus by saCas9 and Multiplex Single-Guide RNAs in
animal models.Mol. Ther. 25, 1168–1186. doi: 10.1016/j.ymthe.2017.03.012
Zhang, R., Andersson, C. E., Savchenko, A., Skarina, T., Evdokimova, E.,
Beasley, S., et al. (2003). Structure of Escherichia coli Ribose-5-phosphate
isomerase: a ubiquitous enzyme of the pentose phosphate pathway and
the calvin cycle. Struct. Lond. Engl. 11, 31–42. doi: 10.1016/S0969-2126(02)
00933-4
Zheng, H., Cooper, D. R., Porebski, P. J., Shabalin, I. G., Handing, K. B.,
and Minor, W. (2017). CheckMyMetal: a macromolecular metal-binding
validation tool. Acta Crystallogr. Sect. Struct. Biol. 73, 223–233.
doi: 10.1107/S2059798317001061
Zhou, Y., Fomovska, A., Muench, S., Lai, B.-S., Mui, E., McLeod, R. (2014).
Spiroindolone that inhibits PfATPase4 Is a potent, cidal inhibitor of
Toxoplasma gondii Tachyzoites in vitro and in vivo. Antimicrob. Agent
Chemother. 58, 1789–92. doi: 10.1128/AAC.02225-13
Conflict of Interest Statement: RM, KE, HM, and JM are inventors on a U.S.
patent (US8575126B2) that is focused on delivery of morpholino oligomers as a
treatment for Toxoplasma gondii infection. JM is employed by Gene Tools, LLC,
the company that manufactured the vivoPMO for this study. However, he took
no part in data collection or analysis. RM has completed an unrelated literature
review for Sanofi-Pasteur.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Citation: Lykins JD, Filippova EV, Halavaty AS, Minasov G, Zhou Y, Dubrovska
I, Flores KJ, Shuvalova LA, Ruan J, El Bissati K, Dovgin S, Roberts CW, Woods
S, Moulton JD, Moulton H, McPhillie MJ, Muench SP, Fishwick CWG, Sabini E,
Shanmugam D, Roos DS, McLeod R, Anderson WF and Ngô HM (2018) CSGID
Solves Structures and Identifies Phenotypes for Five Enzymes in Toxoplasma gondii.
Front. Cell. Infect. Microbiol. 8:352. doi: 10.3389/fcimb.2018.00352
Copyright © 2018 Lykins, Filippova, Halavaty, Minasov, Zhou, Dubrovska, Flores,
Shuvalova, Ruan, El Bissati, Dovgin, Roberts, Woods, Moulton, Moulton, McPhillie,
Muench, Fishwick, Sabini, Shanmugam, Roos, McLeod, Anderson and Ngô. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 21 October 2018 | Volume 8 | Article 352
